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INHIBITION OF NEMATODE DEVELOPMENT WITH THIABENDAZOLE*
ORVILLE J. STONE, M.D., J. FRED 1VIULLINS, M.D. AND CAROLYN J. WILLIS, M.A.
In previous papers (1, 2, 3), the effectiveness of
thiabendazole in "creeping eruption" has been re-
ported, and the other uses of the drug have been
reviewed. Another report (4) described in detail
the observation that this drug has no effect in vitro
on the infective stage of Ancylostoma ceninum lar-
vae. After exsheathment by the use of CO2 the or-
ganism did not become susceptible to thiabendazole.
It was our opinion that the organism must progress
in its development within the skin to a stage ca-
pable of ingesting the drug. It has generally been
assumed that the organism does not progress be-
yond the infective stage within human skin.
Our work was based on the assumption that the
drug itself is effective and that metabolism is not
required. However, almost all published studies on
thiabendazole have been limited to therapy of clini-
cal disease. We know of no previously published
data on in vitro effectiveness against nematodes.
The drug is effective in vitro against the dermato-
phytes (5).
METHOD
The stools of five dogs with known natural honk-
work infection were gathered separately. Each stool
was separately mixed and divided equally into four
petri plates, each containing an equal quantity of
charcoal. Three of the plates from each animal were
used as controls. Thiabendazolet was added to the
other plate in a concentration of 125 micrograms/ml
(the quantity of charcoal was not taken into con-
sideration in figuring the volume, but the volume of
the stool was considered).
The plates were incubated at room temperature
and were examined for larvae at seven and ten days.
Every control plate contained larvae in large quan-
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tities. Every plate with thiabendazole was com-
pletely negative for the development of larvae.
CONCLU5ION
Thiabendazole produced complete inhibition of
development of A. ceninum eggs into infective lar-
vae. To our knowledge this is the first report of in
vitro activity of thiabendazole against a nematode.
This possibly means that the drug is acting un-
changed in the body and not depending on a meta-
bohc product. Or it may be possible that metabolic
changes take place in the parasite, rendering it sus-
ceptible to t he drug.
SUMMARY
Thiabcndazole (125 micrograms/ml) completely
inhibited the development of the infectious stage of
A. caninum from the eggs. The fact that thiabenda-
zole is effective in vitro further substantiates the
impression that the organism is susceptible to the
ingested drug. The clinical effectiveness of the drug
makes it seem likely that the organism progresses
in development within the skin to a stage where it
ingests the drug.
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